Blog
Beyond Trial and Error: AI-Driven Design of Peptide Therapeutics
Beyond Trial and Error: AI-Driven Design of Peptide Therapeutics AI is transforming peptide drug discovery
The Self-Driving Lab: How Automation and AI Are Redefining the Pace of Discovery
The Self-Driving Lab: How Automation and AI Are Redefining the Pace of Discovery Automation and
Engineering Life: How Synthetic Biology Is Tackling Climate Change and Disease
Engineering Life: How Synthetic Biology Is Tackling Climate Change and Disease Synthetic biology enables the
The RNA Revolution: Designing Drugs for a New Class of Targets
The RNA Revolution: Designing Drugs for a New Class of Targets RNA is emerging as
Hitting the Delete Button on Disease: The Rise of Targeted Protein Degraders
Hitting the Delete Button on Disease: The Rise of Targeted Protein Degraders Targeted Protein Degraders
The Protein Architect: How Generative AI Is Building the Drugs of Tomorrow
The Protein Architect: How Generative AI Is Building the Drugs of Tomorrow Generative AI has
Beyond the Microscope: How Cryo-ET is Revealing Disease in Its Native State
Beyond the Microscope: How Cryo-ET is Revealing Disease in Its Native State Cryo-electron tomography (Cryo-ET)
Anti-mutant calreticulin (calr) antibodies and uses thereof
Anti-mutant calreticulin (calr) antibodies and uses thereof The patent discloses antibodies specifically targeting mutant calreticulin
Tricyclic compounds as inhibitors of wrn
Tricyclic compounds as inhibitors of wrn Compounds selectively target WRN helicase, crippling DNA repair in